Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President and CEO Rich Daly and other management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST. The presentation will be webcast from the company’s investor website and a replay will be available for at least 30 days.
The company described itself as a commercial-stage biopharmaceutical focused on in-licensing, developing, and commercializing therapies for rare and difficult-to-treat diseases.
Positive
- None.
Negative
- None.
News Market Reaction – CPRX
In the Dec 15 session, CPRX gained 2.37%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.2% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Conference participation | Neutral | +1.0% | Announced participation in Bank of America CNS Therapeutics Virtual Conference with webcast access. |
| Nov 19 | Growth recognition | Positive | -0.7% | Deloitte Fast 500 ranking with 249% revenue growth over 2021–2024. |
| Nov 18 | Conference participation | Neutral | +0.4% | Planned presentation at Citi’s 2025 Global Healthcare Conference with webcast replay. |
| Nov 05 | Earnings and update | Positive | +0.2% | Q3 2025 results, raised 2025 revenue guidance, cash update, and share repurchase program. |
| Nov 04 | Workplace award | Positive | -0.5% | BioSpace 2026 Best Places to Work recognition with high small‑employer ranking. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate milestones have drawn mixed reactions: one recognition/award headline saw a small decline, while strong earnings and guidance prompted a modest gain.
Over the last several months, Catalyst reported strong Q3 2025 results with $148.4M in revenue, raised full‑year revenue guidance to $565M–$585M, and announced a $200M share repurchase program, alongside substantial cash of $689.9M. The company also received external recognition, ranking #304 on Deloitte’s Fast 500 with 249% revenue growth from 2021–2024, and was named a BioSpace 2026 Best Place to Work. Multiple recent conference participations highlight ongoing investor-relations outreach, with the new J.P. Morgan appearance continuing this pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
Presentation Details
Date: Monday, January 12, 2026
Time: 3:45pm PST
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull or Olipriya Das, Russo Partners (858) 717-2310, (646) 942-5588 david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com